NCI Cancer Center News
Tiny mutation triggers drug resistance for patients with one type of leukemia
A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug. In a correspondence published online May 28 in the New England Journal of Medicine, they show how the mutation triggers resistance.
Click here to read the full press release.
Study mentioned: N Engl J Med. 2014 May 28. [Epub ahead of print]
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib.
No comments:
Post a Comment